Relief Therapeutics Holding SA Stock price

Equities

RLF

CH1251125998

Biotechnology & Medical Research

End-of-day quote Swiss Exchange 07:00:00 2024-03-25 pm EDT 5-day change 1st Jan Change
1.38 CHF -2.82% Intraday chart for Relief Therapeutics Holding SA +6.15% -30.65%
Sales 2021 3.32 3.01 Sales 2022 6.08 5.51 Capitalization 132M 120M
Net income 2021 -34M -30.8M Net income 2022 -50M -45.3M EV / Sales 2021 70,411,981 x
Net cash position 2021 40.5M 36.69M Net cash position 2022 14.89M 13.49M EV / Sales 2022 19,251,190 x
P/E ratio 2021
-6.44 x
P/E ratio 2022
-2.5 x
Employees 69
Yield 2021 *
-
Yield 2022
-
Free-Float 65.87%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.82%
1 week+6.15%
Current month-9.21%
1 month-13.21%
3 months-25.41%
6 months-36.70%
Current year-30.65%
More quotes
1 week
1.32
Extreme 1.32
1.47
1 month
1.30
Extreme 1.3
1.62
Current year
1.30
Extreme 1.3
1.99
1 year
1.30
Extreme 1.3
15.00
3 years
1.30
Extreme 1.3
156.00
5 years
0.32
Extreme 0.32
320.00
10 years
0.32
Extreme 0.32
320.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 22-01-27
Director of Finance/CFO - -
Chairman 46 16-05-24
Members of the board TitleAgeSince
Chairman 46 16-05-24
Chief Operating Officer - 21-05-26
Director/Board Member 56 20-12-16
More insiders
Date Price Change Volume
24-03-27 1.33 -3.62% 23,029
24-03-26 1.38 -2.82% 11,941
24-03-25 1.42 0.00% 15,775
24-03-22 1.42 +8.40% 42,656
24-03-21 1.31 +0.77% 6,347

End-of-day quote Swiss Exchange, March 25, 2024

More quotes
RELIEF THERAPEUTICS Holding SA is a Switzerland-based biopharmaceutical company. The Company's objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need, as well as to focus on developing treatments for respiratory diseases. It specializes in clinical-stage projects based on molecules of natural origin (peptides and proteins with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action in respiratory indications. RLF-100 is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Its RLF-100 is also used for pulmonary sarcoidosis. The Company is also involved in the clinical development of RLF-100 that is in planning stage for other indications in acute and chronic lung diseases.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Chiffre d''affaires - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Relief Therapeutics Holding SA - Swiss Exchange